Arix Bioscience Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	less than a year
Board average tenure	1.5yrs

Recent management updates

Recent updates

CEO

Arix Bioscience has no CEO, or we have no data on them.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Tom Davidson	COO & CFO	less than a year	no data	no data
Laura Craig	Investor Relations Officer	less than a year	no data	no data
Tassos Konstantinou	Managing Director	less than a year	no data	no data
Jade Fletcher	Financial Controller	1.1yrs	no data	no data
Felix Breyer	Associate	no data	no data	no data
Roy Bartel-Taverner	Analyst	no data	no data	no data

0.9yrs

Average Tenure

Experienced Management: 3HY's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Peregrine David Euan Moncreiffe	Independent Non-Executive Chairman	2.8yrs	UK£150.00k	0.58% £ 1.2m
Andrew Smith	Independent Non-Executive Director	1.5yrs	UK£33.00k	no data
Debra Barker	Senior Independent Director	1.5yrs	UK£38.00k	0.040% £ 83.2k

1.5yrs

Average Tenure

61yo

Average Age

Experienced Board: 3HY's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.

Arix Bioscience Management

Management criteria checks 0/4

Key information

Recent management updates

Arix Bioscience plc Announces Resignation of Directors

Independent Non-Executive Chairman recently bought €79k worth of stock

Arix Bioscience plc Announces Resignation of Robert Lyne as Chief Executive Officer, by the End of 2023

Independent Non-Executive Chairman recently bought €87k worth of stock

Independent Non-Executive Chairman recently bought €243k worth of stock

Arix Bioscience plc Announces Resignation of Benny Soffer as Non-Executive Director

Recent updates

Merck Sharp & Dohme LLC completed the acquisition of Harpoon Therapeutics, Inc. (NasdaqCM:HARP).

Investor sentiment improves as stock rises 16%

Arix Bioscience plc Announces Resignation of Directors

Merck Sharp & Dohme LLC entered into an agreement to acquire Harpoon Therapeutics, Inc. (NasdaqCM:HARP) for $410 million.

Merck Sharp & Dohme LLC entered into an agreement to acquire Harpoon Therapeutics, Inc. (NasdaqCM:HARP) for $410 million.

Independent Non-Executive Chairman recently bought €79k worth of stock

New minor risk - Share price stability

First half 2023 earnings released: EPS: UK£0.10 (vs UK£0.24 loss in 1H 2022)

Arix Bioscience plc Announces Resignation of Robert Lyne as Chief Executive Officer, by the End of 2023

Arix Bioscience plc to Report First Half, 2023 Results on Sep 27, 2023

New minor risk - Insider selling

Independent Non-Executive Chairman recently bought €87k worth of stock

Full year 2022 earnings released

Independent Non-Executive Chairman recently bought €243k worth of stock

Arix Bioscience plc Announces Resignation of Benny Soffer as Non-Executive Director

Alexion Pharmaceuticals, Inc. completed the acquisition of LogicBio Therapeutics, Inc. (NasdaqGM:LOGC) from a group of shareholders.

Less than half of directors are independent

Independent Non-Executive Chairman recently bought €90k worth of stock

Alexion Pharmaceuticals, Inc. entered into a definitive agreement to acquire LogicBio Therapeutics, Inc. (NasdaqGM:LOGC) from a group of shareholders for $68.2 million.

First half 2022 earnings released

Arix Bioscience plc Announces Board and Committee Changes

Arix Bioscience plc to Report First Half, 2022 Results on Aug 10, 2022

Arix Bioscience plc, Annual General Meeting, Jun 07, 2022

Full year 2021 earnings released: UK£0.48 loss per share (vs UK£0.97 profit in FY 2020)

Arix Bioscience plc to Report Fiscal Year 2021 Results on May 05, 2022

Less than half of directors are independent

Investor sentiment improved over the past week

Managing Director Christian Schetter has left the company

First half 2021 earnings released: UK£0.30 loss per share (vs UK£0.38 profit in 1H 2020)

Executive Chairman Naseem Amin has left the company

Pfizer Inc. (NYSE:PFE) acquired remaining unknown minority stake in Amplyx Pharmaceuticals, Inc.

Full year 2020 earnings released: EPS UK£0.97 (vs UK£0.54 loss in FY 2019)

Arix Bioscience plc to Report Fiscal Year 2020 Results on Mar 09, 2021

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

New 90-day high: €2.36

Executive Chairman recently bought €416k worth of stock

Investor sentiment improved over the past week

Market bids up stock over the past week

New 90-day high: €1.82

Market bids up stock over the past week

Merck & Co., Inc. (NYSE:MRK) entered into a definitive agreement to acquire VelosBio Inc. from A. M. Pappas Life Science Ventures V, LP, a fund of Pappas Capital, LLC, Arix Bioscience plc (LSE:ARIX) and other shareholders for $2.8 billion.

Market bids up stock over the past week

New 90-day high: €1.70

New 90-day high: €1.16

New 90-day high - €1.08

Arix Bioscience plc to Report First Half, 2020 Results on Sep 08, 2020

CEO

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age